Belite Bio (NASDAQ:BLTE) Price Target Raised to $215.00

Belite Bio (NASDAQ:BLTE) had its target price increased by equities researchers at Leerink Partners from $185.00 to $215.00 in a report released on Friday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Leerink Partners‘s price objective would suggest a potential upside of 28.95% from the stock’s previous close.

Other analysts have also issued reports about the company. Canaccord Genuity Group started coverage on Belite Bio in a report on Friday, September 4th. They set a “buy” rating and a $303.00 price objective for the company. UBS Group reiterated a “buy” rating on shares of Belite Bio in a report on Thursday, September 3rd. Jefferies Financial Group reissued a “hold” rating on shares of Belite Bio in a research report on Wednesday, September 9th. Zacks Research cut Belite Bio from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, August 18th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $245.00 price objective on shares of Belite Bio in a report on Thursday, October 15th. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Belite Bio currently has an average rating of “Moderate Buy” and a consensus target price of $226.27.

Belite Bio Stock Down 1.9%

Belite Bio stock traded down $3.23 during trading hours on Friday, hitting $166.73. The stock had a trading volume of 181,270 shares, compared to its average volume of 190,771. The business’s 50 day simple moving average is $161.02 and its 200-day simple moving average is $160.25. Belite Bio has a one year low of $105.88 and a one year high of $200.00. The stock has a market cap of $6.71 billion, a price-to-earnings ratio of -61.07 and a beta of -1.19.

Belite Bio (NASDAQ:BLTE) last announced its earnings results on Thursday, November 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.19. Research analysts anticipate that Belite Bio will post -3.08 EPS for the current fiscal year.

Insider Activity at Belite Bio

In other Belite Bio news, CFO Hao-Yuan Chuang sold 49,433 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $187.64, for a total value of $9,275,608.12. Following the sale, the chief financial officer directly owned 44,000 shares in the company, valued at $8,256,160. This represents a 52.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Yu-Hsin Lin sold 74,435 shares of Belite Bio stock in a transaction on Friday, September 4th. The shares were sold at an average price of $187.71, for a total value of $13,972,193.85. Following the sale, the chief executive officer directly owned 96,134 shares of the company’s stock, valued at $18,045,313.14. This represents a 43.64% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 168,330 shares of company stock worth $31,969,118. Corporate insiders own 13.29% of the company’s stock.

Institutional Investors Weigh In On Belite Bio

A number of institutional investors have recently made changes to their positions in the business. Affinity Asset Advisors LLC raised its stake in Belite Bio by 225.0% in the first quarter. Affinity Asset Advisors LLC now owns 65,000 shares of the company’s stock worth $10,364,000 after buying an additional 45,000 shares in the last quarter. Candriam S.C.A. bought a new stake in Belite Bio during the 3rd quarter valued at approximately $10,711,000. Renaissance Technologies LLC bought a new stake in Belite Bio during the 1st quarter valued at approximately $8,291,000. The Manufacturers Life Insurance Company purchased a new position in shares of Belite Bio during the 1st quarter worth approximately $3,125,000. Finally, Amundi purchased a new position in shares of Belite Bio during the 1st quarter worth approximately $671,000. Hedge funds and other institutional investors own 0.53% of the company’s stock.

Top Belite Bio Stories

Here are a few of the latest stories about BLTE:

• Positive Sentiment: The FDA accepted Belite Bio’s tinlarebant NDA for priority review, moving the drug closer to a potential first-ever treatment for Stargardt disease. This regulatory milestone may support investor optimism as the FDA review proceeds. Belite Bio Q3 2026 Earnings Call Highlights
• Positive Sentiment: A technical analysis article said shares moved above their 200-day moving average, a trend signal that some investors may view positively. BLTE share price and 200-day moving average
• Negative Sentiment: Belite Bio reported a $30.3 million quarterly net loss. The loss underscores the costs and uncertainty involved in advancing its drug pipeline; the company has not yet established a commercial revenue base. Belite Bio reveals quarterly loss

About Belite Bio

Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.